Levetiracetam
Product Images NDC 67296-1636

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 67296-1636). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 01)

This text provides a simple formula to calculate the total daily dose of a medication based on the patient's weight and the daily dose prescribed in mg/kg/day. The medication's concentration is provided at 100 mg/mL.*

FDA Label Image

Figure 2 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 02)

This appears to be a mathematical equation used in medical contexts to calculate the glomerular filtration rate (GFR) in female patients based on their age, weight, and serum creatinine levels. CLer, which represents the clearance of creatinine, is first calculated by multiplying the difference between 140 and the patient's age by their weight in kilograms and dividing by 72 times their serum creatinine level in milligrams per deciliter. This value is then adjusted for the patient's body surface area by multiplying it by 1.73 and dividing by their BSA (in square meters).*

FDA Label Image

Structure (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 03)

FDA Label Image

Figure 4 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 04)

FDA Label Image

Figure 5 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 05)

This appears to be a chart showing the percentages of patients in a study who received a placebo or varying doses of levetiracetam (an anti-seizure medication). The percentages range from 0% to 35.2%. No further information is available.*

FDA Label Image

Figure 6 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 06)

FDA Label Image

Figure 7 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 07)

This is a table displaying the percentage of patients in a study who may have experienced certain outcomes while taking either a placebo or levetiracetam. The outcomes, represented by percentages in the table, are not provided or labelled. The placebo group included 7 participants, while the levetiracetam group included 101 participants.*

FDA Label Image

Figure 8 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 08)

This text shows the percentage of patients who were given a placebo (N=51) and levetiracetam (N=58) in a clinical trial. 19.6% of patients were in the placebo group while 43.1% were given levetiracetam.*

FDA Label Image

Figure 9 (5a86abbc 0e78 40d3 9ae6 F0cc78815cb5 09)

This appears to be a chart or graph showing the percentage of patients in a study who fall into different categories. The categories are not given, but are represented by percentages ranging from 0% to 100% and by data points labeled with percentages of 10%, 20%, etc. There are two groups of patients listed, one that received a placebo (N=84) and one that received a drug called levetiracetam (N=79). The percentages for each group are listed at various points on the chart, but no explanation is given for what these percentages represent.*

FDA Label Image

Label (Sdistributi19051411500 0001)

This is a medication called Levetiracetam, with a dosage of 500mg per tablet. It comes in a package of 20 tablets, and can only be obtained with a prescription. The lot number is 8021151, with an expiration date of 04/21. The manufacturer is Lupin Limited based in Pithampur, India, and it has been distributed by Redpharm Drug in Eden Prarie, MN. The usual adult dosage is specified in the package insert and it is recommended to store the medication at room temperature.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.